GenVec has received a Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The fund is intended to support the company’s malaria vaccine program.
Reportedly, the grant is valued at approximately $600,000 over two years and will be used to identify new immunogenic antigens for malaria vaccine development.
GenVec will be collaborating with the US Naval Medical Research Center (NMRC), to apply its adenovector technology for the development of malaria vaccine candidates.
Joseph Bruder, head of malaria program of GenVec, said: “We appreciate the support this grant offers GenVec. This funding supports the advancement of GenVec technology by moving GenVec into the antigen discovery phase of vaccine development.”